# BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer

> **NCT01441297** · PHASE2 · COMPLETED · sponsor: **Ji-youn Han** · enrollment: 24 (actual)

## Conditions studied

- Small Cell Lung Cancer
- Small Cell Lung Cancer Recurrent

## Interventions

- **DRUG:** BIBF 1120

## Key facts

- **NCT ID:** NCT01441297
- **Lead sponsor:** Ji-youn Han
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2015-10-31
- **Final completion:** 2016-03-31
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-08-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01441297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01441297, "BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01441297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*